摘要
目的探讨一线化疗药物联合艾迪注射液治疗晚期非小细胞肺癌(NSCLC)的临床疗效、不良反应以及对患者免疫功能的影响。方法回顾性分析90例晚期NSCLC患者的临床资料。根据治疗方式的不同将患者分为对照组和观察组,每组45例。对照组患者仅接受一线化疗方案[鳞癌患者接受吉西他滨+顺铂(GP)化疗方案,腺癌患者接受多西他赛+顺铂(DP)化疗方案],观察组患者在此基础上联合艾迪注射液进行治疗。比较两组患者的近期临床疗效、不良反应发生情况及免疫功能的变化。结果观察组患者的有效率为62.2%(28/45),对照组患者的有效率为51.1%(23/45),两组患者的有效率比较,差异无统计学意义(P﹥0.05)。观察组患者骨髓抑制、胃肠道反应的发生率均低于对照组患者,差异均有统计学意义(P﹤0.05)。治疗后,两组患者T淋巴细胞亚群中CD3^+、CD4^+、CD4^+/CD8^+水平均低于同组治疗前,CD8^+水平高于同组治疗前,差异均有统计学意义(P﹤0.05)。治疗后,观察组患者T淋巴细胞亚群中CD3^+、CD4^+、CD4^+/CD8^+水平均高于对照组患者,CD8^+水平低于对照组患者,差异均有统计学意义(P﹤0.05)。结论一线化疗药物联合艾迪注射液对减轻NSCLC患者的骨髓抑制和胃肠道反应、改善患者机体免疫功能具有一定的作用,值得临床进一步研究。
Objective To discuss the clinical efficacy, adverse reactions and the immune function impact of first-line chemotherapy drugs combined with Aidi injection in the treatment of advanced non-small cell lung cancer（NSCLC）.Method The clinical data of 90 patients with NSCLC were retrospectively analyzed. The patients were divided into the study group and the control group according to whether they received Aidi injection treatment. There were 45 cases in each group. Patients in control group underwent first-line chemotherapy（GP chemotherapy regimen for patients with squamous carcinoma, DP chemotherapy regimen for patients with adenocarcinoma）, and patients in study group were treated with Aidi injection based on the first-line chemotherapy. The clinical efficacy, adverse reactions and changes in immune function were compared in the two groups. Result The response rate in the study group and control group were62.2%（28/45） and 51.1%（23/45） respectively, without significant difference（P〉0.05）. The incidences of myelosuppression and gastrointestinal reactions in the study group were significantly lower than those in the control group（P〈0.05）. In the study group, compared to the levels of T-lymphocyte subsets before treatment, the levels of CD3＋, CD4~＋and CD4~＋/CD8~＋were significantly decreased and the level of CD8~＋was significantly increased（P〈0.05）. After treatment, compared to those in control group, the levels of CD3＋, CD4~＋and CD4~＋/CD8~＋were significantly higher and the level of CD8~＋was significantly lower（P〈0.05）. Conclusion First-line chemotherapy drugs combined with Aidi injection has a positive effect on alleviating myelosuppression and gastrointestinal reactions, improving immune function in patients with NSCLC. It is worthy of further study.
作者
张群
孙学会
李瑞萍
ZHANG Qun;SUN Xuehui;LI Ruiping(Department of Respiratory Medicine;Department of Nephrology,Central Hospital of Zaozhuang Mining Group,Zaozhuang 277000,Shandong,China)
出处
《癌症进展》
2018年第7期866-869,共4页
Oncology Progress
关键词
非小细胞肺癌
艾迪注射液
T淋巴细胞亚群
免疫功能
骨髓抑制
non-small cell lung cancer
Aidi injection
T-lymphocyte subsets
immune function
myelosuppression
